257 related articles for article (PubMed ID: 35259043)
1. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia.
Tettamanti S; Rotiroti MC; Giordano Attianese GMP; Arcangeli S; Zhang R; Banerjee P; Galletti G; McManus S; Mazza M; Nicolini F; Martinelli G; Ivan C; Veliz Rodriguez T; Barbaglio F; Scarfò L; Ponzoni M; Wierda W; Gandhi V; Keating M; Biondi A; Caligaris-Cappio F; Biagi E; Ghia P; Bertilaccio MTS
Leuk Lymphoma; 2022 Jul; 63(7):1566-1579. PubMed ID: 35259043
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Giordano Attianese GM; Marin V; Hoyos V; Savoldo B; Pizzitola I; Tettamanti S; Agostoni V; Parma M; Ponzoni M; Bertilaccio MT; Ghia P; Biondi A; Dotti G; Biagi E
Blood; 2011 May; 117(18):4736-45. PubMed ID: 21406718
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Wang X; Walter M; Urak R; Weng L; Huynh C; Lim L; Wong CW; Chang WC; Thomas SH; Sanchez JF; Yang L; Brown CE; Pichiorri F; Htut M; Krishnan AY; Forman SJ
Clin Cancer Res; 2018 Jan; 24(1):106-119. PubMed ID: 29061640
[No Abstract] [Full Text] [Related]
4. Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.
Faitschuk E; Hombach AA; Frenzel LP; Wendtner CM; Abken H
Blood; 2016 Sep; 128(13):1711-22. PubMed ID: 27535994
[TBL] [Abstract][Full Text] [Related]
5. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
6. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
[TBL] [Abstract][Full Text] [Related]
7. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
[TBL] [Abstract][Full Text] [Related]
8. Tandem bispecific CD123/CLL-1 CAR-T cells exhibit specific cytolytic effector functions against human acute myeloid leukaemia.
Wang XY; Bian MR; Lin GQ; Yu L; Zhang YM; Wu DP
Eur J Haematol; 2024 Jan; 112(1):83-93. PubMed ID: 37712633
[TBL] [Abstract][Full Text] [Related]
9. Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Villa-Álvarez M; Sordo-Bahamonde C; Lorenzo-Herrero S; Gonzalez-Rodriguez AP; Payer AR; Gonzalez-Garcia E; Villa-Álvarez MC; López-Soto A; Gonzalez S
Front Immunol; 2018; 9():2917. PubMed ID: 30619281
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia.
Zou Y; Xu W; Li J
J Hematol Oncol; 2018 Nov; 11(1):130. PubMed ID: 30458878
[TBL] [Abstract][Full Text] [Related]
11. Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia.
Wang G; Sun X; Zuo S; Li C; Niu Q; Xia Y; Meng Y; Liu M; Fang Z; Yang X; Jiang Y; Wang S; Cui H; Huang H; Jiang E; Zhou D; Deng Q; Pan J; Feng X
J Hematol Oncol; 2021 Sep; 14(1):149. PubMed ID: 34530888
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
13. Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia.
Bair SM; Porter DL
Am J Hematol; 2019 May; 94(S1):S10-S17. PubMed ID: 30861173
[TBL] [Abstract][Full Text] [Related]
14. Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells.
Fraietta JA; Schwab RD; Maus MV
Semin Oncol; 2016 Apr; 43(2):291-9. PubMed ID: 27040708
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL.
Collins MA; Jung IY; Zhao Z; Apodaca K; Kong W; Lundh S; Fraietta JA; Kater AP; Sun C; Wiestner A; Melenhorst JJ
Cancer Res Commun; 2022 Sep; 2(9):1089-1103. PubMed ID: 36922932
[TBL] [Abstract][Full Text] [Related]
16. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
17. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia.
Kovalovsky D; Yoon JH; Cyr MG; Simon S; Voynova E; Rader C; Wiestner A; Alejo J; Pittaluga S; Gress RE
Leukemia; 2021 Sep; 35(9):2581-2591. PubMed ID: 33633313
[TBL] [Abstract][Full Text] [Related]
18. Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia.
Aue G; Sun C; Liu D; Park JH; Pittaluga S; Tian X; Lee E; Soto S; Valdez J; Maric I; Stetler-Stevenson M; Yuan C; Nakamura Y; Muranski P; Wiestner A
J Immunol; 2018 Oct; 201(7):1967-1974. PubMed ID: 30104242
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
[TBL] [Abstract][Full Text] [Related]
20. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]